Gene Network Sciences to Use Modeling Software in Collaboration with CombinatoRx
Biosimulation shop Gene Network Sciences said this week that it will use its biological modeling software to assist CombinatoRx in drug efficacy and safety studies.
Financial terms of the agreement were not disclosed.
The parties will use protein expression and transcriptional profiling data generated by CombinatoRx and the GNS proprietary reverse engineering and forward simulation software platform to characterize unanticipated mechanisms underlying the “synergistic interactions” between the components of multi-target therapeutic candidates.
Earlier this year, GNS entered into an agreement with Weill Cornell Medical College to characterize the synergies between two classes of cancer drugs: farnesyl transferase inhibitors and taxanes [BioInform 06-22-07].
InforSense, Affymetrix Join Each Other’s Integration Programs
InforSense announced this week that it has joined the Affymetrix GeneChip-compatible Applications Program, and that its InforSense GenSense solution is compatible with the Affymetrix GeneChip microarray platform.
In addition, Affymetrix has become a member of InforSense's Open Workflow Partner Network, joining over 40 other partners in the program.
The integration enables scientists to analyze and interpret both the Affymetrix Genome-Wide Human SNP 5.0 and SNP 6.0 arrays. Workflows provided with the solution also include access to Affymetrix Power Tools for loss of heterozygosity and copy number variation as well as the Affymetrix calling algorithms, including BRLMM, BRLMM-p, and Birdseed.
The InforSense Open Workflow Partner Network provides interoperability between industry leading technologies via the InforSense platform.
Health Discovery To Gain US, European Patents for Fractal Genomics Modeling
Health Discovery said this week that the US Patent and Trademark Office has issued a notice of allowance for its patent application, "Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets."
Once issued, the patent will be the second of a series of applications covering the company’s so-called “Fractal Genomics Modeling” technology to issue. This patent covers use of the FGM technology to identify patterns within a dataset by recognizing repeated data strings within a long sequence of data.
The points on a grid associated with the sequence matching are then used to create a visual map capable of graphically representing the complete dataset. The claims of the new patent are not limited to biotechnology applications, but also application of the FGM technology to pattern recognition within other types of data.
Health Discovery also said that the European Patent Office has recently granted a new patent covering the FGM technology. The claims of European Patent No. 1,252,588 correspond to those of the first issued US patent covering the FGM technology, Patent No. 6,920,451, which provides for either graphical or mathematical mapping of the points that represent strings of data.
TIGM Deposits Knockout Mouse Sequence Data in Genbank
The Texas Institute for Genomic Medicine said this week that it has deposited more than 275,000 nucleotide sequence tags from its knockout mouse library into the National Institutes of Health's Genbank.
Houston-based TIGM, which joined the International Knockout Mouse Consortium in May, said it offered the genetic sequence information to NIH after the institute called for mouse data to be widely shared throughout the international scientific community.
TIGM said the samples were pulled from its library of C57BL/6 mouse embryonic stem cells and deposited into Genbank’s Genome Survey Sequences division.
The institute said that the deposit is “one of the largest single submissions” to Genbank since it was created in 1982.